Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches
M James Lonie, P Andrew Barbour, Riccardo Dolcetti
CANCER TREATMENT REVIEWS | ELSEVIER SCI LTD | Published : 2021
With an incidence that is constantly rising, oesophageal adenocarcinoma (OAC) is becoming an increasing health burden worldwide. Although significant advances in treatment regimens have improved patient outcomes, survival rates for this deadly cancer remain unsatisfactory. This highlights the need to improve current therapeutic approaches and develop novel therapeutic strategies for treating OAC patients. The advent of immunotherapy has revolutionised treatment across a range of malignancies, however outcomes in OAC show modest results. The inherent resistance of OAC to treatment reflects the complex genomic landscape of this cancer, which displays a lack of ubiquitous driver mutations and l..View full abstract
Awarded by Cancer Council Queensland, Australia
Awarded by National Breast Cancer Foundation, Australia
Awarded by Metro South Health Research Support Scheme Program
This publication was supported by the UQ Graduate School Living Stipend Allowance; the UQ Philip Walker Surgery Research Scholarship; the Cancer Council Queensland, Australia (APP1145758, APP1165063); the National Breast Cancer Foundation, Australia (IIRS-18-47, IIRS-20124, IIRS-21-100); and the Metro South Health Research Support Scheme Program (RSS_2019_027).